Aspen Pharmacare Operating Income 2017-2025 | APNHY
Aspen Pharmacare operating income from 2017 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
|
Aspen Pharmacare Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $79 |
| 2024 | $374 |
| 2023 | $441 |
| 2022 | $571 |
| 2021 | $461 |
| 2020 | $455 |
| 2019 | $339 |
| 2018 | $721 |
| 2017 | $610 |
| 2016 | $625 |
|
Aspen Pharmacare Quarterly Operating Income (Millions of US $) |
|---|
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $4.248B | $2.065B |
| Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |